Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study

Two influenza vaccines are licensed in the U.S. exclusively for the 65 years and older population: a trivalent inactivated high-dose influenza vaccine (HD-IIV3) and a trivalent inactivated adjuvanted influenza vaccine (aIIV3). In a recent publication, we estimated a relative vaccine effectiveness (r...

Descripción completa

Detalles Bibliográficos
Autores principales: van Aalst, Robertus, Gravenstein, Stefan, Mor, Vincent, Mahmud, Salaheddin M., Wilschut, Jan, Postma, Maarten, Chit, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540428/
https://www.ncbi.nlm.nih.gov/pubmed/34696173
http://dx.doi.org/10.3390/vaccines9101065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540428/
https://www.ncbi.nlm.nih.gov/pubmed/34696173
http://dx.doi.org/10.3390/vaccines9101065

Ejemplares similares